Insights into Gastric Cancer

Arun Kumar Vadikari, Vishakante Gowda D, Mahendran Bhaskaran, Vikas Jain*
Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagar, Mysuru-570015, Karnataka, India

Article History:
Received on: 15.09.2019
Revised on: 20.12.2019
Accepted on: 25.12.2019

Keywords:
Anti-Her2 Mab,
Gastric cancer,
Helicobacter pylori,
Monoclonal antibodies,
Multidrug resistance,
Nanoparticles,
Robotic surgery

ABSTRACT
Gastric Cancer (GC) is one of the serious diseases prevailing globally. GC has immense global life-threatening health issues by taking 4th place among all the widespread cancers and 2nd foremost reason for fatality around the globe. Numerous patients have inoperable disease at diagnosis or have recurrent disease after resection with curative intent. In the present review, we have put forward all the possible advanced treatments for GC, which includes the application of Nanotechnology, Monoclonal antibodies, and Robotic surgery. Nanoparticle offers a potentially improved treatment of multidrug-resistant cancers. GC is uniquely positioned as an area of research for targeted and nanoparticle therapies. This review briefs about design and considerations to develop targeted nanoparticle-based approaches for overcoming physiological hurdles in GC treatment. Based on current knowledge, molecular and cellular mechanisms, a number of novel biologic approaches such as monoclonal antibodies have been recently introduced for cancer treatment that mainly affects the immune system or target signaling pathways playing a role in cancer and metastasis development. Surgical robotic systems have been presented into the area of GC therapy as an enhanced technology that has overwhelmed the technical limits of laparoscopy. A note is added to relevant studies dealing with treatment concepts and gives an overview of the latest trends and developments in the treatment of GC.

INTRODUCTION
Gastric Cancer (GC) is one of the serious diseases prevailing globally. GC is an immense global life-threatening health issue, which takes the fourth place among all the widespread cancers and also the second foremost reason for death around the world. Each year over 950000 new cases are identified globally. In 2012, the death rate was found to be nearly 720000 due to this deadly cancer. Figure 1 represents the anatomical classification of gastric cancer.

World widely GC is one among the 4th utmost widespread cancer occurring in males subsequent to lung cancer, prostate cancer, and colorectal cancer and the 5th utmost widespread cancer occurring in females following breast cancer, cervical cancer, colorectal cancer, and lung cancer. The quotient to develop GC in males is double as likely in females (10.9 v/s 5.5 per 100,000) with a peak age occurrence of 60–84 years. Technologically advanced screening activities are required, as is an advancement in diagnostic analysis of GC. GC tends developing deficiency of efficient screening approaches over 50% of patients to stand in advanced GC stages during preliminary diagnosis and at this point, many of
these patients don’t hold the chance for fundamental surgery and are unwilling to take treatment through adjuvant treatment.

A newly evolving body of evidence confirmed that mAb therapy could be an effective treatment in tumors. Using mAbs as monotherapy or adjuvant therapy is increasing in different types of cancer to achieve survival benefits and more efficient treatment. Hybridoma technology developed by Kohlen and Milstein paved the way for mAbs productions and made initial significant changes in clinical oncology.

In this review, the advancement in nanoparticles in the field of cancer is discussed as they emerge as an innovative therapy. Nanoparticles provide the potential for improved possibilities and enhanced therapy of multidrug-resistant cancers. Firstly, the overall mechanism of nanoparticles will be briefed. In addition, an emphasis on the newer technology used to overcome GC is been introduced (Vyas et al., 2014). In this review, an effort is put to discuss the overview of GC, risk factors, treatment approaches and their utilization in the treatment of GC. Figure 2 provides detailed outcomes of the Gastrointestinal Oncology Conference held on September 29th, 2017, at Hershey country club, US (Siegel et al., 2017).

Etiology

The utmost vital reason for sporadic distal GC is Helicobacter pylori (H. pylori) infection. In prolonged inflammation brought by infection of Helicobacter pylori and the subsequent carcinogenesis, together with host, bacterial, and environmental aspects, interrelate to enable damage restoration. Apoptosis (Cell death), the Modified proliferation of cells and few epigenetic alternations to tumor suppressor genes may take place, which can finally cause inflammation linked oncogenesis. Helicobacter pylori are a kind of bacteria that evade the human body and live in the gastrointestinal tract. After several years, these bacteria could form sores in the stomach lining or the lining of the small intestinal upper part. These sores are termed as ulcers. In a few individuals, an infection can cause GC. Infection with Helicobacter pylori is common. Nearly the world’s two-thirds population has such kind of bacteria in their bodies. It doesn’t lead to ulcers or any other symptoms in many individuals (Wang et al., 2014). (See Figure 3)

Epstein-Barr virus is another pathogen-related to GC. This infective agent is found in cancer cells but absent in regular epithelial cells. This infective agent is seen in cancerous tumor cells of 80% of gastric carcinomas having lymphoid stroma. The part of the Epstein-Barr virus in carcinogenesis is still uncertain (Wang et al., 1999). (See Figure 4)

Of all the GC cases, about 10% are associated inside family lines. Inherited case studies are assumed to occupy 1–3% of all GC cases. They comprise of 3 foremost syndromes like Gastric adenocarcinoma and proximal polyposis of the stomach, Familial intestinal GC and Hereditary diffuse GC. About 40% of families suffering from Hereditary diffuse GC show a hereditary basis-causative alteration in the CDH1 (Cadherin 1) and also caused by Mutagenesis in CTNN1 (Catenin alpha 1). GCs are identified in individuals with mutations in TP53 (Li-Fraumeni syndrome), STK11 (Peutz-Jeghers syndrome), or APC (familial adenomatous polyposis). Poor intake of vegetables and fruits, more consumption of nitrates, pickled foods, salts and also smoking have been accompanying an elevated chance for GC. Even Obesity can be a risk aspect for GC.

Classification of Gastric Cancer

Gastric Cancer is a broad term encircling multiple malignancies of varying histology and comprises as mentioned below,

1. Adenocarcinoma
2. Lymphoma
3. Gastrointestinal stromal tumors (GIST)
4. Squamous cell carcinoma
5. Carcinoid tumors
6. Adenocanthoma.

Adenocarcinoma

It is most common, which accounts for >90% of GCs. The Lauren system histopathologically categorizes gastric adenocarcinoma and divides the tumor into two types,

1. Diffuse
2. Intestinal.
Figure 2: Gastrointestinal Oncology Conference

MULTI-DISCIPLINARY PATIENT CARE IN GASTROINTESTINAL ONCOLOGY CONFERENCE

Aim of the Gastrointestinal Oncology conference was to:
1. Identify the risk factors and genetic mutations of cancers in the digestive system for prevention and early detection.
2. Discuss diagnostic modalities and multi-disciplinary treatment of patients with digestive organ cancers.
3. Explore supportive interventions for patients with malignant diseases of the digestive system.

A variety of issues were focused on the frontiers in caring for patients with various gastrointestinal cancers.

Issues were presented by Faculty members of the Penn State Cancer Institute and Penn State Health Milton S. Hershey Medical Centre.

Session’s target audience comprised Primary care physicians, Gastroenterologists, Medical oncologists, Surgical oncologists, Radiation oncologists, Nurse practitioners and Physician assistants.

Figure 3: A: Helicobacter Pylori in the stomach. B: Helicobacter pylori that grow spirally in the mucous layer lining the inside of the human stomach.
Diffuse gastric adenocarcinoma

It tends to progress in younger patients and spreads by direct, transcolomic and lymphatic routes, often resulting in peritoneal disease. A characteristic of this is Submucosal infiltrative growth. It produces a rigid, leather-bottle stomach known as "Linitis Plastica," which can last up to 14% of advanced gastric malignancies.

Intestinal gastric adenocarcinoma

It tends to occur in an older population and affects men more commonly (Male: Female ratio 2:1). It is common in endemic regions, accompanying environmental factors, atrophic gastritis and preferentially spreads hematogenous and typically resulting in liver metastases. Macroscopically, diffuse cancers appear as ulcerating lesions endoscopically, whereas intestinal tumors tend to be exophytic, bulky lesions (Laurén, 1965).

Lymphoma

It occurs in the lymphatic system, a part of the germ-fighting network of the human body, which includes the thymus gland, spleen, bone marrow and lymph nodes (lymph glands). The main subclasses are Hodgkin’s lymphoma and Non-Hodgkin’s lymphoma.

Gastrointestinal stromal tumors

GIST’s are rare tumors occurring in very early forms of special cells, called the interstitial cells of Cajal (ICC) located in the wall of the GIT. ICC are cells of the autonomic nervous system that controls body functions such as digestion of food. ICCs are occasionally termed as the “pacemakers” of the GIT since they give signals to GIT muscles for contraction activity in order to transfer food particles and liquids along the GIT.

Squamous cell carcinomas

Squamous cells are flat cells present in the lining of few areas of the anal end portion and the oesophageal superior portion. Cancers initiating in such cells are known as Squamous cell carcinomas.

Carcinoid tumors

These tumors are a kind of neuroendocrine tumor, typically start in the lungs or the GI tract. They secrete hormones into the human body leading to signs and symptoms, for example, skin flushing or diarrhea.

Adenoacanthoma

It is a malignancy of squamous cells that have differentiated from epithelial cells. It can be present in the endothelium of the uterus, mouth and large intestine (American Cancer Society, 2017).

Risk Factors for Gastric/GEJ Cancers

Numerous harmful aspects were recognized that cause GC like Epstein-Barr virus, Obesity, Helicobacter pylori infection, Dietary aspects like pickled food consumption and red meat and High consumption of salt. A 43% rise in the danger for GC was linked with the consumption of processed red meat. 17.9% of individuals infected with GC have shown the presence of Epstein-Barr virus-encoded small RNA (Wang et al., 1999). The probability of death due to GC was found to be 6 –times greater in individuals diseased with H. Pylori compared to individuals having no infection (Wang et al., 2014).

Environmental Factors

H. pylori infection

Gastritis caused due to infection with H. pylori infection, is known as the major reason for GC. Microbial resistance brought about the progress of vaccination methods to keep H. Pylori Infection in control. But these procedures are unsatisfactory until today. Dietary salt is also a vital aspect that leads to the progress of GC in H. pylori-infected individuals, by promoting H. pylori colonization along with enhancement of CagA (Cytotoxin-associated gene A) expression in H. Pylori (Ogura et al., 2008).

Occupational risk aspects

GC may develop upon exposure to agents like N-nitroso compounds, Asbestos, Nitrogen oxides, Ionizing radiation, Cigarette smoking and Low consumption of vitamins A and C. It’s defined in Chart 1.

Genetic Factors

Modifications in the arrangement of DNA, either by hereditary or acquired, could lead to oncogenic pathway stimulation, directing to the progress and
approximately 40% of hereditary GCs harbour transmuted CDH1, which leads to faulty or declined E-cadherin expression, which would lead to the stimulation of EGFR (EGF) (Epid dermal Growth Factor Receptor).

**Somatic mutations**

Variability in chromosomes comprises a modification in chromosomal numbers that may vary areas in designated chromosomes, which might lead to transformed gene expression. Intestinal GC is connected with acquiring a copy number of chromosomal regions 20q, 17q, and 8q. This leads to greater expression of c-ErbB2 and EGF (epidermal growth factor). Diffuse GCs are connected with acquiring copy number at 13q and 12q areas of chromosomes and subsequent FGFR overexpression (fibroblast growth factor receptor), HER2 (Human epidermal growth factor receptor 2) overexpression along with c-myc overexpression. Therefore, GC patients exhibiting HER2 overexpression can be efficiently cured with trastuzumab, a mAbs focused against HER2 (Mclean and El-Omar, 2014).

Table 1 explains various risk factors related to the progress of GC (Sjödahl et al., 2007), and Table 2 is regarding the Worldwide prevalence of the most important types of gastrointestinal malignancies and related mortality rate (Ferlay et al., 2010).

**The Role of Nanotechnology in Gastrointestinal Cancer**

Nanoparticles possess a size range of nanometres that have the ability to carry loaded active drugs to cancer cells, enhancing the specificity of treatment and perhaps reducing drug resistance. Their application in the area of cancer takes benefit from the pathophysiology of tumors such as inadequate lymphatic drainage, greater penetrability, and retention effect along with the microenvironment.

**Nanoparticles for Cancer Treatment**

Nanoparticles are a promising means in diagnostics, treatment and medical imaging. They act as a target delivery tool and help in the delivery through two different methods, passive and active targeting. Active targeting employs antibodies, receptors, and peptides to identify tumor antigens as a means to offer target delivery. Passive targeting employs the improved penetrability and retention (EPR) effect seen in tumor vasculature as a means to assist cancer treatment. With the utilization of nanoparticles in the treatment of cancer, selectivity is enhanced and accidental systemic injury is strongly prevented. Nanoparticles not only take benefit of the improved permeability of tumors but also take advantage of the decreased lymphatic clearance of tumorous tissue compared to healthy tissue. This absence of clearance permits for the withholding of the nanoparticle and the drug it carries to stay in the tumors for an extended period of time, permitting for progressive therapeutic efficacy.

In addition, as an imaging tool, nanoparticles provide an enhancement in the sensitivity and specificity of diagnostic imaging, presenting a non-invasive and precise technique. Nanotechnology-based imaging probes are intended to identify a biomarker located on the cell surface of interest. The nanoparticles are supportive in refining the difference between cancerous and non-cancerous tissue. (See Figure 5) (Fang et al., 2011). The method adopted is a unique type of fluorescent nanoparticles identified as Quantum Dots (QDs) have acquired momentum as an approach to enhance the imaging signal. QDs release photons of light of numerous wavelengths upon excitation. The benefit of those nanoparticles in diagnostic imaging over the conventionally used contrast agents is their low cost of synthesis and easy application. Additionally, current discovery is the application of nanoparticles in an MRI. It is well furnished that superparamagnetic iron oxide nanoparticles with lymphotropic qualities have been confirmed to efficaciously intensify the finding of tumors above 5 mm when compared to unenhanced MRI or computed tomography. Application of iron/iron oxide core/shell nanoparticles have extraordinary magnetic properties and may identify small tumors.

**Outline of Gastrointestinal Therapy Developments in Gastric Cancer**

Nanomedicine has demonstrated to have utility and potential use for GC treatment and diagnosis. The application of fluorescent magnetic nanoparticles is a clear illustration of the applicability of nanoparticles in GC. In contrast to traditional fluorescent dyes, fluorescent nanoparticles (FNPs) use tumor vasculature’s EPR (enhanced permeability and retention)
### Table 1: Risk aspects in GC

| Risk factor                  | Observation                                                                 | Risk Ratio (RR) |
|------------------------------|------------------------------------------------------------------------------|-----------------|
| Helicobacter pylori          | Most vital modifiable risk factor                                            | 2.5%– 3%        |
| Smoking                      | Linked with increased risk of disease reappearance. The intensity of GC is   | 1.5%            |
|                              | almost doubled in smokers.                                                   |                 |
| Alcohol                      | RR~1 in light/moderate drinkers and higher with heavy consumption.           | ~1% or higher   |
| Dietary salt and food        | Salt-based preservatives and lack of refrigeration results in an increased   | ~1% with each gram of | |
| preservation                 | risk                                                                          | salt consumed/day|                 |
| Fruit and vegetables         | Reduced consumption leads to increased risk                                 | ~0.5%           |
| Pernicious anemia            | People with anemia (a smaller number of RBCs) have a greater risk of GC.    | 6.8%            |
| Obesity                      | Being overweight or obese is a possible cause of cancers of the cardia.     |                 |
| Genetics                     | Hereditary diffuse GC -produced due to alteration in the E-cadherin gene.    |                 |
|                              | 67% cumulative GC risk. Increased colon and lobular breast cancer risk.      |                 |
|                              | Lynch syndrome -defective DNA mismatch repair (MLH1 or MSH2 mutation).      |                 |
|                              | Increased risk of GC and colon cancer.                                       |                 |

### Table 2: The Mortality rate of GC

| Category                              | Worldwide occurrence among all cancers (%) | Mortality                  | Key Points                   |
|---------------------------------------|------------------------------------------|----------------------------|------------------------------|
| Worldwide occurrence                  | 3.8%                                     | 5.4% of cancer deaths globally | 6th highest cancer mortality |
| mortality (5-year survival rate in the USA) | 7.8%                                     | 9.7%                       | 2nd highest cancer mortality |
| Liver                                 | 7.9%                                     | 9.2%                       | 3rd highest cancer mortality |
| Pancreas                              | 2.2%                                     | 5-year survival rate       | Lowest 5-year survival among |
| Gall Bladder                          | 1.1%                                     | in the USA                 | GI cancers                   |
| Colon                                 | 9.8%                                     | 1.4%                       | Higher frequency in USA & EUROPE (13.3%) |
phenomenon to its advantage to stay inside tumor tissue, making FNPs an attractive choice for in vivo tumor imaging. Moreover, FNPs' large surface area and core-shell structure permit the manufacture of multimodal nanoparticles (MMNPs). MMNPs are derived by combining optical imaging modalities with nonoptical based imaging modalities. Such probes can further be packed with therapeutic cancer drugs together with the cancer-targeting agent. Recent advances have revealed that the overexpression of cyclooxygenase 2 (COX-2) elevates the lymphangiogenesis of tumors by elevating the expression of VEGF. COX-2 has been the target of several remedies in GC treatment. Consequently, inhibition of COX-2 holds the ability as a possibly effective target of chemotherapy. The use of Ursolic Acid (UA), an inhibitor of COX-2, as a chemotherapeutic agent, has been known for some time. However, the hydrophobicity of UA makes it exhibit low bioavailability and poor pharmacokinetics in vivo.

Moreover, it possesses a lack of specificity for cancer cells and causes toxicity to other tissues. To solve this matter, a UA-loaded nanoparticle was designed by Nano-precipitation utilizing amphiphilic methoxy poly (ethylene glycol)-polycaprolactone (MPEG-PCL) block copolymers as UA carriers. Through an MTT assay and DAPI staining, UA-NPs were discovered to efficiently cause more death of cells by a greater inhibition of COX-2, caspase 3 activations, and greater cytotoxicity than UA alone. Such investigations recommend UA as a promising delivery system of UA in GC treatment (Zhang et al., 2013).

Small interfering RNA (siRNA) facilitates the cleavage of target mRNA molecules that results in gene silencing at very specific sites. So, their application induces the silencing of cancer genes that have been identified to be related to the progress of cancer. Such genes comprise those accountable for proliferative oncogenes and inhibition of apoptosis. Their use in the field of nanotechnology was established in a study where liposomal nanoparticles were used in GC as treatment. These nanoparticles are bilayer membrane structures, made of phospholipids that have the ability to encapsulate hydrophilic agents such as therapy drugs and small interfering RNA (siRNA). The latter opens the opportunity for gene therapy in the field of cancer. More ever, during a study done in the last year, CD44 isoforms such as CD44v6 were preferred as target genes for the inhibition and finding of metastatic GC cells. The target gene was then effectively downregulated and quietened through the application of Iron oxide superparamagnetic nanoparticles (PEG-g-PEI-SPION) as a delivery technique of siRNA. These nanoparticles were preferred for their MRI visibility and transfection efficiency. This study renders PEG-PEFI-SPION a probable and efficient non-viral vector for cancer gene therapy (Chen et al., 2013).

Finally, additional treatment of GC takes the benefit of the carrier properties nanoparticles to have. This
Figure 6: Illustration of targeted micelle nanoparticles loaded with both paclitaxel and tetrandrine, eventually bringing the apoptosis of cancer cells.

Table 3: Information on nanoparticle technology therapies for gastric cancer

| Category       | Treatment                                                                 | Key points                                                                 |
|----------------|---------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Gastric cancer | 1. Fluorescent nanoparticle imaging                                       | 1. Coupled to antibodies for highly expressed receptors                    |
|                | 2. PEG-PEI liposomes                                                      | 2. Target chemo and siRNA therapy                                          |
|                | 3. Ursolic acid nanoparticle to suppress overexpressed COX-2              | 3. Increases bioavailability and effectiveness of ursolic acid             |
|                | 4. Nanoparticles coloaded with paclitaxel and tetrandrine                | 4. Tetrandrine induced ROS formation increases paclitaxel efficiency       |

is shown by the study done by Li et al. in the co-loading of Paclitaxel/tetrandrine nanoparticles as a therapy for GC. During this research, it was detected that the resistance ability of cancer cells to Paclitaxel treatment was overwhelmed by co-administration of Tetrandrine (Tet). The part of Tet in this therapy was to bring production of reactive oxygen species which overwhelmed intracellular antioxidant capacity and permitted for an intensification of Paclitaxel potential against the tumorous cells as seen in Figure 6 (Li et al., 2012). This entire procedure was named oxidation treatment.

Key Points

Nanoparticles provide the opportunity of an enhanced and earlier diagnosis of cancer, permitting the localized therapy of neoplasms and tumor cells, reducing the potential side effects that occur with the presently used therapies. They provide the potential for enhanced multidrug-resistant therapy of multidrug-resistant cancers.

The smaller size of nanoparticles also rises their solubility in the bloodstream and their ability to spread into tissue with smaller pore sizes, providing them an extensive range of accessibility and tissue penetration.

A significant part of gastrointestinal cancers are not responsive to the recent chemotherapeutic and radiotherapeutic agents; additional advancement of nanoparticle approaches demonstrates a promising tool in their potential efficacy. (See Table 3) (Vyas et al., 2014).

Limitations and Challenges of Nanotechnology

The high cost of development which would prevent extensive access to the advantages of the technology, even in primary stages. The usage of nanoparticles may be restricted by the science of cancer cells in their frequency of efficiency. If a particular molecular target has developed resistance to treatment, nanoparticles can assist to solve this by permitting more intracellular accumulation of the therapeutic agent, and limited uptake by healthy tissues, thus overcoming the resistance (Vyas et al., 2014).

Role of Monoclonal Antibodies for Gastric Cancer Treatment
Even though several therapies are now available for GC, the 3-year and 5-year OS (overall survival) rates are still less than 35% and 25% correspondingly. The symptoms are nonspecific during the initial phases of GC. More specific symptoms, for example, weight loss and anemia, are observed in progressive stages. But effective treatment choices are limited in advanced phases and the average survival is 9–10 months. For years, therapy choices for cancer have been chemotherapy and radiation with great chances of tumor degeneration resulting from drug resistance. All this information highlights the requirement for further novel and efficient anticancer treatments. One of the recent approaches in advanced cancer therapy is Immunotherapy. Together with the growing number of clinical studies and investigation of biomarkers and clinical data, a desirable role of immunotherapy in GC is evolving. Intracellular and extracellular pathways accountable for cell proliferation, apoptosis and angiogenesis could be suitable targets for cancer immunotherapy. The earliest observation of using immunotherapy in cancer goes back to 1891 when William B Coley injected the streptococcal microorganism into cancer patients and detected shrinkage of the cancer cells.

Overexpression of VEGF (Vascular endothelial growth factor) and its receptor (VEGFR) (Vascular endothelial growth factor receptor) was observed in 40% of GC case reports and was connected with the progressive phase of cancer and poor diagnosis. By means of a VEGFR-2 monoclonal antibody (mAb) such as ramucirumab progresses survival in GC. Overexpression of human EGF receptor 2 (Her2) was also observed in advanced GC, and anti-Her2 mAbs like trastuzumab presented survival benefits in those patients.

The capability of an immune system to identify and terminate non-self-cells (such as cancer cells) before they can cause harm, is known as immune surveillance. Scientific usage of tumor immunotherapy is supporting the immune system towards more potentiated passive or active immune responses against cancer. Usage of mAbs as monotherapy or adjuvant therapy is growing in various categories of cancer to attain survival benefits and more prominent treatment. Hybridoma technology developed by Kohlen and Milstein surfaced the technique for mAbs productions and made preliminary significant changes in clinical oncology. These days, new modalities, which have significant benefits due to their small sizes, such as specific tumor targeting, high affinity, and low immunogenicity, have been established. Cancer immunotherapy utilizing tumor antigen (Ag)-specific mAbs, which makes tumor Ags available to the destructive effects of the immune system. Abs exercise their anti-tumor properties through mechanisms like Agglutination, Neutralizing signaling proteins and Occupying ligand-binding sites on receptors. An example of the latter is inhibition of growth factor ligand-receptor binding with subsequent inhibition of tumor cell growth. Trastuzumab is a mAb that exhibits by this mechanism in breast cancer. Additionally, mAbs have milder side effects (allergic side effects) compared with cytotoxic drugs used in chemotherapy.

The latest approaches under research in tumor therapy consist of Epidermal GC receptor (EGFR) inhibitors, Anti-angiogenesis agents, Apoptosis promoters and Specific immunotherapies.

**Anti-Her2 mAb**

Her2 is a tyrosine-kinase receptor associated with regulation of proliferation, differentiation, and apoptosis. The expression of Her2 in cancer cells is greater than noncancer cells. Overexpression of Her-2 is connected with tumor development and aggressiveness (tumor size, invasion, and metastasis), and has negative properties on overall survival (OS), making it a significant prognostic marker. Her2 overexpression was observed in breast, ovarian, lung, prostate cancers and it was first stated in GC by Saki et al. and Fukushige et al. in 1986. The intermediate proportion of Her2 overexpression was observed in gastrointestinal adenocarcinoma found to be 22%. In the systematic analysis, Jorgensen et al. determined that patients with Her2+GC exhibit significant higher stages of cancer and poor survival.
Table 4: Clinical Studies data of Trastuzumab in Gastric cancer.

| Author (year) | Study name/phase | Monoclonal antibody | Mechanism | Regimen | Results | Safety Profile |
|---------------|-----------------|---------------------|------------|---------|---------|----------------|
| Sawaki et al. (2012) | ToGA | Trastuzumab | Inhibition of Her2 | Trastuzumab+ chemotherapy (G1) versus chemotherapy alone (G2) | MOS: 15.9 months in G1 and 17.7 months in G2 | All grade SD: 51% G1 & 50% G2 Grade≥3 SD: 43% G1 & 36% G2 |
| Thuss-Patience et al. (2017) | GATSBY (Phase II/III) | Trastuzumab | Inhibition of Her2 | Trastuzumab versus docetaxel | MOS: 7.9 months with trastuzumab emtansine given at 2.4 mg/kg weekly and 8.6 months with taxane | In general, the rate of SDs was lower in the trastuzumab group versus taxane group |

MOS: Median overall survival; MRD: Median remission duration; RR: Response rate; SD: Standard deviation; DCR: Disease control rate.

Trastuzumab (Herceptin) is a mAb that targets Her2 acting by several approaches like Inhibition of Her2 dimerization, Inducing receptor destruction and Antibody-associated cytotoxicity. It was the earliest molecular-targeted therapy that resulted in survival benefits in advanced gastric and oesophageal cancer. Inhibitory actions of trastuzumab were first witnessed on human GC cell lines in invitro outcomes, and it presented synergistic antineoplastic action together with chemotherapy in in-vivo studies (Sawaki et al., 2012). The toxic effect of trastuzumab is Cardiotoxicity. This dose-independent side effect is generally reversible after the termination of Trastuzumab. Refer Table 4 for detailed information on Clinical studies of Trastuzumab in Gastric Cancer (Sawaki et al., 2012; Thuss-Patience et al., 2017).

Anti EGFR mAbs

EGFR (Epithelial growth factor receptor) is an additional type of tyrosine kinase growth factor receptor superfamily and is a potential target in cancer immunotherapy. Expression of EGFR occurs in various tissues like skin, gut, kidney and leads to tumor growth and invasion. EGFR overexpression was stated in 27–64% of GC cases and EGFR inhibition might be a potentially ideal target for GC treatment. Refer Figure 7 for the Flow chart illustrating the action of EGFR.

Two categories of EGFR inhibitors studied in GC involved,

1. Oral Tyrosine Kinase Inhibitors Gefitinib and Erlotinib
2. mAbs: - Cetuximab, Panitumumab, and Matuzumab

Cetuximab

It is an anti-EGFR mAb, binding to EGFR and diminishes ligand-receptor interaction. Satisfactory outcomes of preclinical and Phase II clinical trial studies proposed that cetuximab has efficient survival benefits, safe and efficient therapeutic actions in advanced gastroesophageal cancer, mainly when used together with chemotherapy.

Panitumumab

Panitumumab is an entirely humanized anti-EGFR mAb that can increase the survival rate in advanced colorectal cancer. In Phase III, clinical studies have shown by Weddelletal et al., the combinational regimen of oxaliplatin, capectabine, and epirubicin without or with panitumumab were verified on 522 patients suffering from gastroesophageal adenocarcinoma. They stated that there was no increase in OS with a combination of panitumumab and EOG regimen (Waddell et al., 2013).

Matuzumab

Matuzumab is another entirely humanized anti-EGFR mAb. Trackback et al., showing Phase
Table 5: Clinical studies of Anti-EGFR Monoclonal Antibodies in Gastric Cancer

| Author          | Study name/phase | Monoclonal antibody | Mechanism                  | Regimens                          | Results                          | Safety profile                  |
|-----------------|------------------|---------------------|----------------------------|-----------------------------------|----------------------------------|---------------------------------|
| Lordick et al.  | EXPAND (Phase III)| Cetuximab           | Inhibition of EGFR         | Cetuximab+ chemotherapy (G1)      | Median PFS: 4-4 months G1 vs. 5.6 months G2 | Any grade of serious SDs: 54% G1 vs. 44% G2; Grade 3-4 SDs: 83% G1 vs. 77% G2 |
| Waddell et al.  | REAL3 (Phase III)| Panitumumab         | Inhibition of EGFR         | Panitumumab modified-dose         | Median OS: 8.8 months G1 vs. 11.3 months G2 | The higher incidence of grade 3-4 of non-hematologic SDs & lower rate of hematologic SDs was observed in G1 |
| Trarbach et al. | Phase I          | Matuzumab           | Inhibition of EGFR         | Matuzumab+ chemotherapy           | ORR: 26.7% (modest antitumor activity) | Acceptable safety |

MOS: Median overall survival; MRD: Median remission duration; PFS: Progression-free survival; SD: Side effect; DCR: Disease control rate.

I clinical studies to explore matuzumab plus 5-fluorouracil, leucovorin, and cisplatin. The study confirmed the satisfactory safety profile of this treatment in advanced gastric and gastroesophageal adenocarcinoma patients with intermediate anticancer action (Trarbach et al., 2013). Refer Table 5 for detailed information on clinical studies of Anti-EGFR Monoclonal Antibodies in Gastric Cancer (Waddell et al., 2013; Lordick et al., 2013).

**Anti-VEGF mAb**

Senger et al. first presented VEGF (Vascular endothelial growth factor) as a vascular permeability factor. It is identified as a significant agent in physiological and pathological angiogenesis. Angiogenesis has vital roles in cancer growth. Overexpression of VEGF and VEGFR was observed in 36–40% of GC patients. Studies have revealed that greater serum VEGF levels potentially connected with inadequate prognosis in GC patients. Therefore, in vivo studies displayed antitumoral actions of anti-VEGFR treatment, possibly facilitated by decreasing tumor vascularity and elevated endothelial cell apoptosis. Using VEGF-A and VEGFR2 (Vascular endothelial growth factor receptor 2) inhibitors might be an alternative approach in cancer treatment to decrease metastasis and tumor vessel supply.

**Ramucirumab**

In Phase III REGARD clinical studies, the ramucirumab monotherapy was observed on 355 formerly treated GEJ adenocarcinoma or advanced gastric patients belonging to 29 countries. Patients separated into 2 categories: Placebo group and ramucirumab group (8 mg/kg given through IV route once every two weeks). The outcomes of this clinical study recommended that ramucirumab has survival benefits as monotherapy in earlier treated advanced gastric or GEJ adenocarcinoma patients (Fuchs et al., 2013).
Table 6: Clinical studies of Anti-VEGF Monoclonal Antibodies in Gastric Cancer.

| Study name/phase | Monoclonal antibody | Regimen | Results | Safety profile | Ref |
|------------------|---------------------|---------|---------|----------------|-----|
| REGARD (Phase 3) | Ramucirumab         | Ramucirumab monotherapy with 8 mg/kg, intravenously once every two weeks or placebo | Median OS: 5.2 months with Ramucirumab vs. 3.8 months with placebo | A similar rate of SDs except for a higher hypertension rate in the ramucirumab arm | Fuchs et al. (2014) |
| Phase 2          | Bevacizumab         | B-DOCT: Trastuzumab+ bevacizumab + docetaxel, oxaliplatin + capecitabine | Median PFS: 10.8 months OS: 17.9 months 1-year OS: 79% 1-year PFS: 52% ORR: 74% | Safe and tolerable | Meulendijks et al. (2016) |

Formerly, Bevacizumab

Bevacizumab is one more anti-VEGF mAb used in malignancies like non-small-cell lung cancer (NSCLC), breast, colorectal and ovarian. This mAb prevents the association between VEGF-A and its receptors VEGFR1 and VEGFR2. Phase I clinical trial recommended efficient advantages in GC. In a single-arm Phase II clinical trial by Didier Meulendijks et al., combination therapy was employed in 3-weekly cycles for six cycles in 25 HER2 + GC patients. The regimen involved bevacizumab, trastuzumab, docetaxel, oxaliplatin, and capecitabine (B-DOCT). The outcomes were efficient and two patients were free of disease 2 years after therapy. This combination therapy is safe and tolerable (Meulendijks et al., 2016). Refer Table 6 for detailed information on clinical studies of Anti-VEGF Monoclonal Antibodies in GC.

Robotic Surgery for Gastric Cancer

Development of Robotic-assisted surgery was performed for use in general and paediatric surgery, gynaecology, and urology. Surgical robotic systems have been presented into the area of GC therapy as an enhanced technology that has overwhelmed the technical limits of laparoscopy. Since 2005, a robotic system has been employed for GC surgery in Korea, and several skilled MIS specialists have stated that in comparison with laparoscopic gastrectomy, robotic gastrectomy is safe and effective. In comparison with laparoscopic surgery, robotic surgery usage for GC suggestively reduces intraoperative blood loss. After robotic gastrectomy, the duration of stay in the hospital is short compared to an open surgical operation. But the time period required for an operation involving robotic gastrectomy was lengthier. Some researchers have recommended that the possibility and benefits of robotic surgery to deal technically-challenging difficult case aspects (for example, very advanced cancer, multiorgan resection, and function preserving surgeries) should be examined. Advantages of Robotic surgery inpatient care includes Multi-articulated movement, reduced hand tremor, the stable and firm camera platform, and much accurate, specific dissections. Disadvantages include nonappearance of tactile feeling and expensive.

Song et al. conveyed their understanding of 100 patients suffering from early GC who undertook robot-assisted gastrectomy (33 total and 67 subtotals, with D1 lymphadenectomy) using the da Vinci system. The average operative time, length of stay and lymph node yield were 231 minutes, 7.8 days and 36.7, respectively. There were no deaths. Even though other studies reveal assessing the safety of robotic gastrectomies has been carried out, but additional multi-center, potential, and relative trials are necessary. Figure 8 illustrates the Layout of the Da Vinci Surgical System comprises the patient cart, vision cart and surgeon console (Coratti et al., 2013).

Table 7 is regarding the Patents obtained in the field of Nanotechnology that explains about the various applications of Nanoparticles for the diagnosis and therapy of cancers (Cui et al., 2015).
Table 7: Patents Obtained in the field of Nanotechnology

| S. NO | Document | Document Title | Claim |
|-------|----------|----------------|-------|
| 1     | US20190032050A1 | RNA nanoparticle for treatment of GC | An artificial RNA nanostructure molecule, comprising: a multiple branched RNA junction motifs comprising at least one RNA oligonucleotides, and a GC-targeting module coupled to the RNA junction motif. |
| 2     | US20180369422A1 | Nanoparticles for cancer detection | A method of detecting a cancer cell or tumor in a subject by administering into the peritoneum, a nanoparticle that comprises a detectable agent and detecting said nanoparticle at the site of a cancer cell or tumor, thereby detecting the cancer cell or tumor. |
| 3     | US20160213711A1 | Cancer Therapy with Silver Nanoparticles | A method of inhibiting the growth or proliferation of a cancer cell comprising contacting the cancer cell with an effective amount of silver nanoparticles. |
| 4     | US20160151298A1 | Docetaxel polymeric nanoparticles | A method of treating a solid tumor cancer inpatient by intravenously administering the patient an effective amount of therapeutic nanoparticle suspension comprising docetaxel, a surfactant, and an aqueous suspending medium. |
| 5     | US20190022246A1 | Silicon nanoparticle with platinum anti-cancer agent | A silica nanoparticle comprising a platinum anti-cancer agent, wherein the platinum anti-cancer agent is conjugated to silica directly, through an oxygen linker, or a nitrogen linker. |
| 6     | US20170020816A1 | Targeted polymerized nanoparticles for cancer treatment | A hybrid polymerized liposomal nanoparticle, comprising: a polymerizable lipid with at least one PEGylated polymerizable lipid having a PEG polymer chain; and a non-polymerizable lipid. |
| 7     | US20190076457A1 | Nanoparticle to target cancer | A pharmaceutical salt comprising polyethylene glycol-block-poly(L-lysine) polymer moiety, a cholecystokinin-B (CCK-B) receptor-ligand and a siRNA complexed with the poly(L-lysine) of the polymer moiety. |
| 8     | US8242165B2 | Mucoadhesive nanoparticles for cancer treatment | Treating cancer by a plurality of nanoparticle comprising glyceryl monooleate fatty acid ester core and surface layer, placing chitosan on the surface layer to create a positive charge to make each nanoparticle more mucoadhesive to negatively charged mucin of cancer cell and incorporating cancer therapeutic agents into the core. |
CONCLUSIONS

GC is a malignant disease with a generally deprived long-term prognosis. The majority of GCs are sporadic subtypes that are strongly associated with environmental risk factors. In the last few decades, various mechanisms of GC genesis have been elucidated, which has resulted in primary and secondary prevention, such as healthy lifestyle and H. pylori eradication. Consequently, the incidence of GC has started to decline. Every patient with GC needs to be treated according to the individual plan made by MDT. Recent advances in molecular targeting to improve on this outcome led to the development of trastuzumab as a new standard of care for HER2-positive patients with GC. But as only about 20% of the patients with GC are HER2 positive, this therapy addresses their needs effectively but not others. Similarly, ramucirumab is able to control the disease and improve outcomes in patients with VEGFR2-positive GC. Further work needs to develop more effective and specific therapies that hopefully have fewer adverse events compared with the currently available therapeutic regimens. Nanoparticles offer the possibility of improved and earlier diagnosis of cancer. In addition, their characteristics allow for the localized treatment of neoplasms and cancer cells, decreasing the potential side effects that come with the currently used treatments. They can also encapsulate drugs and prevent them from having a toxic effect on healthy tissue during their transit to their sites of action. In the utilization of nanoparticles in the field of cancer, it will be important to consider the cost to patients. Although the promising effectiveness of nanoparticles is overwhelming, the question of whether this would be affordable to patients is still unclear. Advancement has been made in understanding the pathogenesis and the molecular biology of GC and in optimizing the available treatment options and modalities. However, in the future, the focus should be on further unraveling the taxonomy of GC, fine-tuning treatment strategies, and developing new drugs for patients with advanced GC.

REFERENCES

American Cancer Society 2017. Gastrointestinal stromal tumor: What is Gist?
Chen, Y., Lian, G., Liao, C., Wang, W., Zeng, L., Qian, C., Shuai, X. 2013. Characterization of polyethylene glycol-grafted polyethyleneimine and superparamagnetic iron oxide nanoparticles (PEG-g-PEI-SPION) as an MRI-visible vector for siRNA delivery in gastric cancer in vitro and in vivo. Journal of Gastroenterology, 48(7):809–821.
Coratti, A., Annecchiarico, M., Marino, M. D., Gentile, E., Coratti, F., Giuliani, P. C. 2013. Robot-assisted Gastrectomy for Gastric Cancer: Current Status and Technical Considerations. World Journal of Surgery, 37(12):2771–2781.
Cui, D., Zhang, C., Liu, B., Shu, Y., Du, T., Shu, D., Guo, P. 2015. Regression of Gastric Cancer by Systemic Injection of RNA Nanoparticles Carrying both Ligand and siRNA. Scientific Reports, 5(1):10726–10726.
Fang, J., Nakamura, H., Maeda, H. 2011. The EPR
effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. *Advanced Drug Delivery Reviews*, 63(3):136–151.

Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., Parkin, D. M. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *International Journal of Cancer*, 127(12):2893–2917.

Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Tabernero, J. 2014. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma ( REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. *The Lancet*, 383:61719–61724.

Laurén, P. 1965. The two Histological Main types of Gastric Carcinoma: diffuse and So-called Intestinal-Type Carcinoma. *Acta Pathologica Microbiologica Scandinavica*, 64(1):31–49.

Li, X., Lu, X., Xu, H., Zhu, Z., Yin, H., Qian, X., Liu, B. 2012. Paclitaxel/Tetrandrine Coloaded Nanoparticles Effectively Promote the Apoptosis of Gastric Cancer Cells Based on “Oxidation Therapy. *Molecular Pharmaceutics*, 9(2):222–229.

Lordick, F., Kang, Y. K., Chung, H. C., Salman, P., Oh, S. C., Bodoky, G., Moehler, M. 2013. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. *The Lancet Oncology*, 14(6):70102–70107.

Mclean, M. H., El-Omar, E. M. 2014. Genetics of gastric cancer. *Nature Reviews Gastroenterology & Hepatology*, 11(11):664–674.

Meulendijks, D., Beerepoot, L. V., Boot, H., Groot, J. W. B. D., Los, M., Boers, J. E., Cats, A. 2016. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study. *Investigational New Drugs*, 34(1):119–128.

Ogura, K., Hirata, Y., Yanai, A., Shibata, W., Ohmae, T., Mitsuno, Y., Yoshida, . . ., H. 2008. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. *Journal of clinical gastroenterology*, 42(3):279–283.

Ruan, J., Song, H., Qian, Q., Li, C., Wang, K., Bao, C., Cui, D. 2012. HER2 monoclonal antibody conjugated RNase-A-associated CdTe quantum dots for targeted imaging and therapy of gastric cancer. *Biomaterials*, 33(29):7093–7102.

Sawaki, A., Ohashi, Y., Omuro, Y., Satoh, T., Hamamoto, Y., Boku, N., Ohtsu, A. 2012. Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. *Gastric Cancer*, 15(3):313–322.

Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., Jemal, A. 2017. Colorectal cancer statistics. *CA: A Cancer Journal for Clinicians*, 67(3):177–193.

Sjödahl, K., Lu, Y., Nilsen, T. I. L., Ye, W., Hveem, K., Vatten, L., Lagergren, J. 2007. Smoking and alcohol drinking in relation to risk of gastric cancer: A population-based, prospective cohort study. *International Journal of Cancer*, 120(1):128–132.

Thuss-Patience, P. C., Shah, M. A., Ohtsu, A., Cutsem, E. V., Ajani, J. A., Castro, H., Kang, Y. K. 2017. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. *The Lancet Oncology*, 18(5):640–653.

Trarbach, T., Przyborek, M., Schleucher, N., Heeger, S., Lüpertz, C., Vanhoefer, U. 2013. Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas. *Investigational New Drugs*, 31(3):642–652.

Vyas, D., Castro, P., Saadeh, Y., Vyas, A. 2014. The Role of Nanotechnology in Gastrointestinal Cancer. *Journal of Biomedical Nanotechnology*, 10(11):3204–3218.

Waddell, T., Chau, I., Cunningham, D., Gonzalez, D., Okines, A. F. C., Wotherspoon, A., Barbachano, Y. 2013. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. *The Lancet Oncology*, 14(6):481–489.

Wang, F., Meng, W., Wang, B., Qiao, L. 2014. Helicobacter pylori-induced gastric inflammation and gastric cancer. *Cancer Letters*, 345(2):196–202.

Wang, H. H., Wu, M. S., Shun, C. T., Wang, H. P., Lin, C. C., L. J. 1999. Lymphoepithelioma-like carcinoma of the stomach: a subset of gastric carcinoma with distinct clinicopathological features and high prevalence of Epstein-Barr virus infection. *Hepatogastroenterology*, 46(26):1214–1219.

Zhang, H., Li, X., Ding, J., Xu, H., Dai, X., Hou, Z., Sun, W. 2013. Delivery of ursolic acid (UA) in polymeric nanoparticles effectively promotes the apoptosis
of gastric cancer cells through enhanced inhibition of cyclooxygenase 2 (COX-2). International Journal of Pharmaceutics, 441(1-2):261–268.